Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 237 articles:
HTML format
Text format



Single Articles


    December 2017
  1. ROLLA S, De Mercanti SF, Bardina V, Horakova D, et al
    Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
    J Neuroimmunol. 2017;313:89-91.
    PubMed     Text format     Abstract available


  2. BHAT R, Mahapatra S, Axtell RC, Steinman L, et al
    Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine.
    J Neuroimmunol. 2017;313:77-81.
    PubMed     Text format     Abstract available


  3. TAYLOR JM
    Tissue resident macrophages are sufficient for demyelination during peripheral nerve myelin induced experimental autoimmune neuritis?
    J Neuroimmunol. 2017;313:69-76.
    PubMed     Text format     Abstract available


  4. LI R, Sun X, Shu Y, Wang Y, et al
    Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients.
    J Neuroimmunol. 2017;313:56-60.
    PubMed     Text format     Abstract available


  5. GILLI F, Royce DB, DiSano KD, Pachner AR, et al
    Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;313:34-40.
    PubMed     Text format     Abstract available


  6. LIU J, Lian Z, Chen H, Shi Z, et al
    Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: A systematic review and meta-analysis.
    J Neuroimmunol. 2017;313:25-33.
    PubMed     Text format     Abstract available


  7. AKAISHI T, Kaneko K, Himori N, Takeshita T, et al
    Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2017;313:10-15.
    PubMed     Text format     Abstract available


  8. BANSI J, Koliamitra C, Bloch W, Joisten N, et al
    Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training.
    J Neuroimmunol. 2017 Dec 6. pii: S0165-5728(17)30420.
    PubMed     Text format     Abstract available


    November 2017
  9. KIM MJ, Lim JY, Park SA, Park SI, et al
    Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis.
    J Neuroimmunol. 2017 Nov 29. pii: S0165-5728(17)30134.
    PubMed     Text format     Abstract available


  10. MONTELEONE F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, et al
    Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.
    J Neuroimmunol. 2017 Nov 20. pii: S0165-5728(17)30179.
    PubMed     Text format     Abstract available


  11. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Corrigendum to Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders" [J. Neuroimmunol. 310. (2017) 150-157].
    J Neuroimmunol. 2017;312:66.
    PubMed     Text format    


  12. WANG Y, Zhang W, Yin J, Lu Q, et al
    Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes.
    J Neuroimmunol. 2017;312:59-65.
    PubMed     Text format     Abstract available


  13. HESSELMARK E, Bejerot S
    Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel.
    J Neuroimmunol. 2017;312:31-37.
    PubMed     Text format     Abstract available


  14. SVEINSSON O, Granqvist M, Forslin Y, Blennow K, et al
    Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.
    J Neuroimmunol. 2017;312:15-18.
    PubMed     Text format     Abstract available


  15. ROLF L, Muris AH, Theunissen R, Hupperts R, et al
    Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
    J Neuroimmunol. 2017 Nov 10. pii: S0165-5728(17)30208.
    PubMed     Text format     Abstract available


  16. MAZDEH M, Moradi N, Khoshroo E, Shayesteh Z, et al
    Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    J Neuroimmunol. 2017 Nov 8. pii: S0165-5728(17)30405.
    PubMed     Text format     Abstract available


    October 2017
  17. LIU W, Zhu M, Yu Z, Yin D, et al
    Therapeutic effects of diosgenin in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Oct 31. pii: S0165-5728(17)30191.
    PubMed     Text format     Abstract available


  18. PALTERER B, Brugnolo F, Sieni E, Barilaro A, et al
    Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation.
    J Neuroimmunol. 2017;311:10-13.
    PubMed     Text format     Abstract available


  19. LEI HW, Wang JY, Dang QJ, Yang F, et al
    Neuropsychiatric involvement in lupus is associated with the Nogo-a/NgR1 pathway.
    J Neuroimmunol. 2017;311:22-28.
    PubMed     Text format     Abstract available


  20. HUANG ZL, Pandya D, Banta DK, Ansari MS, et al
    Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis.
    J Neuroimmunol. 2017;311:40-48.
    PubMed     Text format     Abstract available


    September 2017
  21. FERNANDEZ HURST N, Zanetti SR, Baez NS, Bibolini MJ, et al
    Diazepam treatment reduces inflammatory cells and mediators in the central nervous system of rats with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017 Sep 30. pii: S0165-5728(17)30297.
    PubMed     Text format     Abstract available


  22. MERKER M, Eichler S, Herrmann AM, Wiendl H, et al
    Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 21. pii: S1521-6616(17)30639.
    PubMed     Text format     Abstract available


  23. BADIHIAN S, Manouchehri N, Badihian N
    More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 18. pii: S0165-5728(17)30401.
    PubMed     Text format    


  24. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Text format     Abstract available


  25. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Text format     Abstract available


  26. JAHAN I, Ahammad RU, Farzana KS, Khalid MM, et al
    Tumor necrosis factor-alpha -863C/A polymorphism is associated with Guillain-Barre syndrome in Bangladesh.
    J Neuroimmunol. 2017;310:46-50.
    PubMed     Text format     Abstract available


  27. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Text format     Abstract available


  28. HAITAO R, Huiqin L, Tao Q, Xunzhe Y, et al
    Autoimmune encephalitis associated with vitiligo?
    J Neuroimmunol. 2017;310:14-16.
    PubMed     Text format     Abstract available


  29. DELGADO-GARCIA G, Corona-Vazquez T
    IgG4-related disease and IgG4-mediated neurological autoimmune disorders: One and the same?
    J Neuroimmunol. 2017;310:129-130.
    PubMed     Text format    


  30. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Text format     Abstract available


  31. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells.
    J Neuroimmunol. 2017;310:51-59.
    PubMed     Text format     Abstract available


  32. ZHU DS, Yu L, Li M, Han L, et al
    High serum creatinine is associated with reduction of vision impaired in patients with NMOSD.
    J Neuroimmunol. 2017;310:32-37.
    PubMed     Text format     Abstract available


  33. WANG J, Yang C, Zhao Q, Zhu Z, et al
    Microglia activation induced by serum of SLE patients.
    J Neuroimmunol. 2017;310:135-142.
    PubMed     Text format     Abstract available


  34. LINDSEY JW
    Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
    J Neuroimmunol. 2017;310:131-134.
    PubMed     Text format     Abstract available


  35. ALVARENGA MP, Fernandez O, Leyva L, Campanella L, et al
    The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.
    J Neuroimmunol. 2017;310:1-7.
    PubMed     Text format     Abstract available


  36. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Text format     Abstract available


  37. LAZARIDIS K, Dalianoudis I, Baltatzidi V, Tzartos SJ, et al
    Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2017 Sep 6. pii: S0165-5728(17)30332.
    PubMed     Text format     Abstract available


    August 2017
  38. YESHOKUMAR AK, Gordon-Lipkin E, Arenivas A, Cohen J, et al
    Neurobehavioral outcomes in autoimmune encephalitis.
    J Neuroimmunol. 2017 Aug 31. pii: S0165-5728(17)30274.
    PubMed     Text format     Abstract available


  39. ALVAREZ BRAVO G, Yusta Izquierdo A, Carvalho Monteiro G, Sanchez I, et al
    Cerebellopathy secondary to anti-peroxidase antibody-mediated toxicity. A special case of Hashimoto encephalopathy.
    J Neuroimmunol. 2017 Aug 19. pii: S0165-5728(17)30265.
    PubMed     Text format     Abstract available


  40. LIU RT, Zhang P, Yang CL, Pang Y, et al
    ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response.
    J Neuroimmunol. 2017 Aug 18. pii: S0165-5728(17)30182.
    PubMed     Text format     Abstract available


  41. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Text format     Abstract available


  42. WALLWITZ U, Brock S, Schunck A, Wildemann B, et al
    From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.
    J Neuroimmunol. 2017;309:77-81.
    PubMed     Text format     Abstract available


  43. PITAROKOILI K, Kohle F, Motte J, Fatoba O, et al
    Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis.
    J Neuroimmunol. 2017;309:58-67.
    PubMed     Text format     Abstract available


  44. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Text format     Abstract available


  45. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Text format     Abstract available


  46. MATHEY EK, Garg N, Park SB, Nguyen T, et al
    Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
    J Neuroimmunol. 2017;309:41-46.
    PubMed     Text format     Abstract available


  47. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Text format     Abstract available


  48. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Text format     Abstract available


  49. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Text format     Abstract available


  50. LI X, Lin J, Pan S, Weng Y, et al
    Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;309:68-71.
    PubMed     Text format     Abstract available


  51. KON T, Ueno T, Suzuki C, Nunomura J, et al
    Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer.
    J Neuroimmunol. 2017;309:38-40.
    PubMed     Text format     Abstract available


  52. LIU J, Shi Z, Lian Z, Chen H, et al
    Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population.
    J Neuroimmunol. 2017;309:23-30.
    PubMed     Text format     Abstract available


  53. HENDRICKX DAE, van Eden CG, Schuurman KG, Hamann J, et al
    Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology.
    J Neuroimmunol. 2017;309:12-22.
    PubMed     Text format     Abstract available


  54. SUCHDEV K, Razmjou S, Venkatachalam P, Khan OA, et al
    Late onset neuromyelitis optica mimicking an acute stroke in an elderly patient.
    J Neuroimmunol. 2017;309:1-3.
    PubMed     Text format     Abstract available


  55. AHMAD SF, Ansari MA, Nadeem A, Bakheet SA, et al
    Adenosine A2A receptor signaling affects IL-21/IL-22 cytokines and GATA3/T-bet transcription factor expression in CD4+ T cells from a BTBR T+ Itpr3tf/J mouse model of autism.
    J Neuroimmunol. 2017 Aug 9. pii: S0165-5728(17)30253.
    PubMed     Text format     Abstract available


  56. WILDNER P, Selmaj KW
    Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
    J Neuroimmunol. 2017 Aug 2. pii: S0165-5728(17)30263.
    PubMed     Text format     Abstract available


    July 2017
  57. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Text format     Abstract available


    June 2017
  58. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Text format     Abstract available


  59. ASMAIL A, Kesler A, Drory VE, Kolb H, et al
    Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel.
    J Neuroimmunol. 2017;307:47-52.
    PubMed     Text format     Abstract available


  60. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Text format     Abstract available


  61. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Text format     Abstract available


  62. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Text format     Abstract available


  63. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Text format     Abstract available


  64. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Text format     Abstract available


  65. BARROS PO, Dias ASO, Kasahara TM, Ornelas AMM, et al
    Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients.
    J Neuroimmunol. 2017;307:82-90.
    PubMed     Text format     Abstract available


    May 2017
  66. JING S, Song Y, Song J, Pang S, et al
    Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074.
    PubMed     Text format     Abstract available


  67. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Text format     Abstract available


  68. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Text format     Abstract available


  69. CONSTANTINESCU R, Krysl D, Andren K, Asztely F, et al
    Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.
    J Neuroimmunol. 2017;306:25-30.
    PubMed     Text format     Abstract available


  70. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Text format     Abstract available


  71. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Text format     Abstract available


  72. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Text format     Abstract available


    April 2017
  73. RAIBAGKAR P, Ferry JA, Stone JH
    Is MuSK myasthenia gravis linked to IgG4-related disease?
    J Neuroimmunol. 2017;305:82-83.
    PubMed     Text format     Abstract available


  74. MORIGUCHI K, Miyamoto K, Kusunoki S
    4-Aminopyridine ameliorates experimental autoimmune neuritis in Lewis rats.
    J Neuroimmunol. 2017;305:72-74.
    PubMed     Text format     Abstract available


  75. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Text format     Abstract available


  76. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Text format     Abstract available


  77. BROWN MP, Hissaria P, Hsieh AH, Kneebone C, et al
    Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.
    J Neuroimmunol. 2017;305:16-18.
    PubMed     Text format     Abstract available


  78. ZHANG M, Liu RT, Zhang P, Zhang N, et al
    Parthenolide inhibits the initiation of experimental autoimmune neuritis.
    J Neuroimmunol. 2017;305:154-161.
    PubMed     Text format     Abstract available


  79. ADAMCZYK-SOWA M, Bieszczad-Bedrejczuk E, Galiniak S, Rozmilowska I, et al
    Oxidative modifications of blood serum proteins in myasthenia gravis.
    J Neuroimmunol. 2017;305:145-153.
    PubMed     Text format     Abstract available


  80. MIFFLIN KA, Frieser E, Benson C, Baker G, et al
    Voluntary wheel running differentially affects disease outcomes in male and female mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017;305:135-144.
    PubMed     Text format     Abstract available


  81. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Text format     Abstract available


  82. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Text format     Abstract available


  83. WANG Q, Xing C, Hao Y, Shi Q, et al
    Memory B cells in Guillain-Barre syndrome.
    J Neuroimmunol. 2017;305:1-4.
    PubMed     Text format     Abstract available


  84. AGLIARDI C, Guerini FR, Zanzottera M, Bolognesi E, et al
    Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort.
    J Neuroimmunol. 2017;305:92-95.
    PubMed     Text format     Abstract available


  85. DENG B, Liu XN, Li X, Zhang X, et al
    Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome.
    J Neuroimmunol. 2017;305:84-91.
    PubMed     Text format     Abstract available


  86. BENEDEK G, Zhang J, Nguyen H, Kent G, et al
    Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice.
    J Neuroimmunol. 2017;305:59-67.
    PubMed     Text format     Abstract available


  87. ZHOU L, Huang Y, Li H, Fan J, et al
    MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients.
    J Neuroimmunol. 2017;305:19-28.
    PubMed     Text format     Abstract available


  88. SCOTT TF
    Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.
    J Neuroimmunol. 2017;305:162-166.
    PubMed     Text format     Abstract available


  89. PAWLAK-ADAMSKA E, Nowak O, Karabon L, Pokryszko-Dragan A, et al
    PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.
    J Neuroimmunol. 2017;305:115-127.
    PubMed     Text format     Abstract available


  90. KIMURA A, Takemura M, Saito K, Serrero G, et al
    Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:175-181.
    PubMed     Text format     Abstract available


    February 2017
  91. PANT AB, Wang Y, Mielcarz DW, Kasper EJ, et al
    Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    J Neuroimmunol. 2017;303:22-30.
    PubMed     Text format     Abstract available


  92. LAZARIDIS K, Baltatzidi V, Trakas N, Koutroumpi E, et al
    Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.
    J Neuroimmunol. 2017;303:13-21.
    PubMed     Text format     Abstract available


  93. WARNECKE A, Musunuri S, N'diaye M, Sandalova T, et al
    Nitration of MOG diminishes its encephalitogenicity depending on MHC haplotype.
    J Neuroimmunol. 2017;303:1-12.
    PubMed     Text format     Abstract available


  94. DEPAULA-SILVA AB, Hanak TJ, Libbey JE, Fujinami RS, et al
    Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.
    J Neuroimmunol. 2017 Feb 12. pii: S0165-5728(16)30480.
    PubMed     Text format     Abstract available


    January 2017
  95. ZHANGBAO J, Zhou L, Li X, Cai T, et al
    The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients.
    J Neuroimmunol. 2017;302:49-55.
    PubMed     Text format     Abstract available


  96. NAKAHARA K, Nakane S, Nakajima M, Yamashita S, et al
    Effect of thymectomy for thymic atrophy in myasthenia gravis: A retrospective study on 93 patients.
    J Neuroimmunol. 2017 Jan 12. pii: S0165-5728(16)30355.
    PubMed     Text format     Abstract available


    December 2016
  97. ALVARENGA-FILHO H, Salles M, Hygino J, Ferreira TB, et al
    Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients.
    J Neuroimmunol. 2016 Dec 30. pii: S0165-5728(16)30393.
    PubMed     Text format     Abstract available


  98. ANNUNZIATA P, Cioni C, Mugnaini C, Corelli F, et al
    Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
    J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274.
    PubMed     Text format     Abstract available


  99. PAOLICELLI D, Manni A, D'Onghia M, Direnzo V, et al
    Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    J Neuroimmunol. 2016 Dec 21. pii: S0165-5728(16)30371.
    PubMed     Text format     Abstract available


  100. MATUTE-BLANCH C, Rio J, Villar LM, Midaglia L, et al
    Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 18. pii: S0165-5728(16)30310.
    PubMed     Text format     Abstract available


  101. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Text format     Abstract available


  102. GORDON-LIPKIN E, Calabresi PA
    Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 14. pii: S0165-5728(16)30447.
    PubMed     Text format     Abstract available


  103. HOSSAIN MJ, Tanasescu R, Gran B
    Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.
    J Neuroimmunol. 2016 Dec 13. pii: S0165-5728(16)30448.
    PubMed     Text format     Abstract available


  104. MOMCILOVIC M, Stamenkovic V, Jovanovic M, Andjus PR, et al
    Tenascin-C deficiency protects mice from experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016 Dec 7. pii: S0165-5728(16)30207.
    PubMed     Text format     Abstract available


    November 2016
  105. HAGHMORAD D, Mahmoudi MB, Salehipour Z, Jalayer Z, et al
    Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 26. pii: S0165-5728(16)30423.
    PubMed     Text format     Abstract available


  106. PROKOPOVA B, Hlavacova N, Vlcek M, Penesova A, et al
    Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis.
    J Neuroimmunol. 2016 Nov 19. pii: S0165-5728(16)30241.
    PubMed     Text format     Abstract available


  107. ACHIRON A, Zilkha-Falb R, Mashiach R, Gurevich M, et al
    RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30209.
    PubMed     Text format     Abstract available


  108. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Angiogenic factors are associated with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30304.
    PubMed     Text format     Abstract available


  109. ZHANG Y, Liu G, Duan Y, Han X, et al
    Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China.
    J Neuroimmunol. 2016 Nov 16. pii: S0165-5728(16)30187.
    PubMed     Text format     Abstract available


  110. HAITAO R, Yingmai Y, Yan H, Fei H, et al
    Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy.
    J Neuroimmunol. 2016;300:9-10.
    PubMed     Text format     Abstract available


  111. MURIS AH, Smolders J, Rolf L, Thewissen M, et al
    Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study.
    J Neuroimmunol. 2016;300:47-56.
    PubMed     Text format     Abstract available


  112. DIAS-CARNEIRO RP, von Glehn F, Moraes AS, Boldrini VO, et al
    MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.
    J Neuroimmunol. 2016;300:30-35.
    PubMed     Text format     Abstract available


  113. GUASP M, Sola-Valls N, Martinez-Hernandez E, Gil MP, et al
    Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).
    J Neuroimmunol. 2016;300:15-17.
    PubMed     Text format     Abstract available


  114. KALINOWSKA-LYSZCZARZ A, Michalak S, Pawlak MA, Losy J, et al
    Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis.
    J Neuroimmunol. 2016;300:11-14.
    PubMed     Text format     Abstract available


  115. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Text format     Abstract available


  116. IWASA K, Furukawa Y, Yoshikawa H, Yamada M, et al
    Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis.
    J Neuroimmunol. 2016 Nov 9. pii: S0165-5728(16)30378.
    PubMed     Text format     Abstract available


  117. LV Z, Shi Q, Huang W, Xing C, et al
    MicroRNA expression profiling in Guillain-Barre syndrome.
    J Neuroimmunol. 2016 Nov 4. pii: S0165-5728(16)30374.
    PubMed     Text format     Abstract available


  118. HAAS J, Schwarz A, Korporal-Kuhnke M, Jarius S, et al
    Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 2. pii: S0165-5728(16)30258.
    PubMed     Text format     Abstract available


  119. AHARONI R, Rosen C, Shezen E, Bar-Lev DD, et al
    Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 1. pii: S0165-5728(16)30381.
    PubMed     Text format     Abstract available


    October 2016
  120. SAMUKAWA M, Kuwahara M, Morikawa M, Ueno R, et al
    Electrophysiological assessment of Guillain-Barre syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type.
    J Neuroimmunol. 2016 Oct 24. pii: S0165-5728(16)30348.
    PubMed     Text format     Abstract available


  121. MELIEF J, Koper JW, Endert E, Moller HJ, et al
    Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
    J Neuroimmunol. 2016;299:84-89.
    PubMed     Text format     Abstract available


  122. FENOGLIO C, De Riz M, Pietroboni AM, Calvi A, et al
    Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    J Neuroimmunol. 2016;299:81-83.
    PubMed     Text format     Abstract available


  123. DA COSTA DS, Hygino J, Ferreira TB, Kasahara TM, et al
    Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:8-18.
    PubMed     Text format     Abstract available


  124. PULIDO MA, DerHartunian MK, Qin Z, Chung EM, et al
    Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.
    J Neuroimmunol. 2016;299:70-78.
    PubMed     Text format     Abstract available


  125. BETTINI M, Gonorazky H, Chaves M, Fulgenzi E, et al
    Immune-mediated rippling muscle disease and myasthenia gravis.
    J Neuroimmunol. 2016;299:59-61.
    PubMed     Text format     Abstract available


  126. BRIKEN S, Rosenkranz SC, Keminer O, Patra S, et al
    Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2016;299:53-58.
    PubMed     Text format     Abstract available


  127. WANG J, Zhao C, Kong P, Bian G, et al
    Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response.
    J Neuroimmunol. 2016;299:45-52.
    PubMed     Text format     Abstract available


  128. JONS D, Kneider M, Fogelstrand L, Jeppsson A, et al
    Early hematopoiesis in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:158-163.
    PubMed     Text format     Abstract available


  129. DOOLEY MM, de Gannes SL, Fu KA, Lindsey JW, et al
    The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
    J Neuroimmunol. 2016;299:147-151.
    PubMed     Text format     Abstract available


  130. WALLER R, Woodroofe MN, Wharton SB, Ince PG, et al
    Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
    J Neuroimmunol. 2016;299:139-146.
    PubMed     Text format     Abstract available


  131. ZHANG F, Liu G, Bu Y, Ma X, et al
    Expression profile of long noncoding RNAs and mRNAs in peripheral blood mononuclear cells from myasthenia gravis patients.
    J Neuroimmunol. 2016;299:124-129.
    PubMed     Text format     Abstract available


  132. MANE-MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    J Neuroimmunol. 2016;299:112-117.
    PubMed     Text format     Abstract available


  133. LIM JA, Lee ST, Moon J, Jun JS, et al
    New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2.
    J Neuroimmunol. 2016;299:107-111.
    PubMed     Text format     Abstract available


  134. MAGGI P, Sati P, Massacesi L
    Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset.
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30306.
    PubMed     Text format     Abstract available


  135. CROSS AH, Song SK
    "A new imaging modality to non-invasively assess multiple sclerosis pathology".
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30328.
    PubMed     Text format     Abstract available


  136. REICH DS
    Imag(in)ing multiple sclerosis: Time to take better pictures.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30307.
    PubMed     Text format     Abstract available


  137. ITOH N, Kim R, Peng M, DiFilippo E, et al
    Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30308.
    PubMed     Text format     Abstract available


    September 2016
  138. BOIOCCHI C, Monti MC, Osera C, Mallucci G, et al
    Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis.
    J Neuroimmunol. 2016;298:189-93.
    PubMed     Text format     Abstract available


  139. TAO Y, Zhang X, Markovic-Plese S
    Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    J Neuroimmunol. 2016;298:181-8.
    PubMed     Text format     Abstract available


  140. DOURADO ME JUNIOR, Ferreira LC, Freire-Neto FP, Jeronimo SM, et al
    No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barre Syndrome in a Brazilian population.
    J Neuroimmunol. 2016;298:160-4.
    PubMed     Text format     Abstract available


  141. MENG QF, Zhang Z, Wang YJ, Chen W, et al
    Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells.
    J Neuroimmunol. 2016;298:138-45.
    PubMed     Text format     Abstract available


  142. OZGUN-ACAR O, Celik-Turgut G, Gazioglu I, Kolak U, et al
    Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice.
    J Neuroimmunol. 2016;298:106-16.
    PubMed     Text format     Abstract available


  143. COSENTINO M, Zaffaroni M, Legnaro M, Bombelli R, et al
    Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
    J Neuroimmunol. 2016;298:82-9.
    PubMed     Text format     Abstract available


  144. LEBRUN C, Bourg V, Bresch S, Cohen M, et al
    Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
    J Neuroimmunol. 2016;298:79-81.
    PubMed     Text format     Abstract available


  145. KARNI A, Asmail A, Drory VE, Kolb H, et al
    Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms.
    J Neuroimmunol. 2016;298:58-62.
    PubMed     Text format     Abstract available


  146. HONG Y, Li HF, Skeie GO, Romi F, et al
    Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
    J Neuroimmunol. 2016;298:51-7.
    PubMed     Text format     Abstract available


  147. HORSTMANN L, Kuehn S, Pedreiturria X, Haak K, et al
    Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;298:32-41.
    PubMed     Text format     Abstract available


  148. MIYAZAKI Y, Niino M, Kanazawa I, Suzuki M, et al
    Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
    J Neuroimmunol. 2016;298:24-31.
    PubMed     Text format     Abstract available


  149. EFTHYMIOU G, Dardiotis E, Liaskos C, Marou E, et al
    Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.
    J Neuroimmunol. 2016;298:19-23.
    PubMed     Text format     Abstract available


  150. TANAKA M, Tanaka K
    Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;298:16-8.
    PubMed     Text format     Abstract available


  151. BERG J, Mahmoudjanlou Y, Duscha A, Massa MG, et al
    The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor.
    J Neuroimmunol. 2016;298:9-15.
    PubMed     Text format     Abstract available


    August 2016
  152. ZHANG Y, Liu G, Han X, Dong H, et al
    The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
    J Neuroimmunol. 2016;297:127-31.
    PubMed     Text format     Abstract available


  153. KEIL M, Sonner JK, Lanz TV, Oezen I, et al
    General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation.
    J Neuroimmunol. 2016;297:117-26.
    PubMed     Text format     Abstract available


  154. PUTHENPARAMPIL M, Miante S, Federle L, Zanetta C, et al
    BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset.
    J Neuroimmunol. 2016;297:63-7.
    PubMed     Text format     Abstract available


  155. SHENG JR, Rezania K, Soliven B
    Impaired regulatory B cells in myasthenia gravis.
    J Neuroimmunol. 2016;297:38-45.
    PubMed     Text format     Abstract available


  156. CALA CM, Moseley CE, Steele C, Dowdy SM, et al
    T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.
    J Neuroimmunol. 2016;297:1-8.
    PubMed     Text format     Abstract available


  157. LOVETT-RACKE AE
    Contribution of EAE to understanding and treating multiple sclerosis.
    J Neuroimmunol. 2016 Aug 12. pii: S0165-5728(16)30195.
    PubMed     Text format     Abstract available


    July 2016
  158. RACKE MK
    Therapeutic developments for autoimmune demyelinating diseases: Musing from an MD (mouse doctor).
    J Neuroimmunol. 2016 Jul 20. pii: S0165-5728(16)30157.
    PubMed     Text format     Abstract available


  159. LEVIN MC, Lee S, Gardner LA, Shin Y, et al
    Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30155.
    PubMed     Text format     Abstract available


  160. NIMMAGADDA VK, Makar TK, Chandrasekaran K, Sagi AR, et al
    SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30158.
    PubMed     Text format     Abstract available


  161. VALENZUELA RM, Kaufman M, Balashov KE, Ito K, et al
    Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    J Neuroimmunol. 2016 Jul 2. pii: S0165-5728(16)30137.
    PubMed     Text format     Abstract available


    June 2016
  162. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    Corrigendum to "An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility" [Journal of Neuroimmunology 290 (2016) 115-118].
    J Neuroimmunol. 2016;295-296:164.
    PubMed     Text format    


  163. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].
    J Neuroimmunol. 2016;295-296:163.
    PubMed     Text format    


  164. HUANG Q, Xiao B, Ma X, Qu M, et al
    MicroRNAs associated with the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2016;295-296:148-61.
    PubMed     Text format     Abstract available


  165. ANSARI QESHMI S, Dabbagh F, Borhani Haghighi A, Ghasemi Y, et al
    Bioinformatics evaluation of the possibility of heat shock proteins as autoantigens in multiple sclerosis based on molecular mimicry hypothesis.
    J Neuroimmunol. 2016;295-296:100-21.
    PubMed     Text format     Abstract available


  166. KUCUKERDEN M, Huda R, Tuzun E, Yilmaz A, et al
    MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    J Neuroimmunol. 2016;295-296:84-92.
    PubMed     Text format     Abstract available


  167. NAKANE S, Higuchi O, Hamada Y, Maeda Y, et al
    Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barre syndrome.
    J Neuroimmunol. 2016;295-296:54-9.
    PubMed     Text format     Abstract available


  168. CHEN Y, Xing XW, Zhang JT, Wang RX, et al
    Autoimmune encephalitis mimicking sporadic Creutzfeldt-Jakob disease: A retrospective study.
    J Neuroimmunol. 2016;295-296:1-8.
    PubMed     Text format     Abstract available


    May 2016
  169. RAINE CS
    Multiple sclerosis: The resolving lesion revealed.
    J Neuroimmunol. 2016 May 27. pii: S0165-5728(16)30129.
    PubMed     Text format     Abstract available


  170. CATANZARO G, Pucci M, Viscomi MT, Lanuti M, et al
    Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016;294:32-40.
    PubMed     Text format     Abstract available


  171. HAAS J, Schwarz A, Korporal-Kuhnke M, Faller S, et al
    Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
    J Neuroimmunol. 2016;294:18-26.
    PubMed     Text format     Abstract available


  172. ERDUR H, Scholz V, Streitz M, Hammer M, et al
    EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
    J Neuroimmunol. 2016;294:14-7.
    PubMed     Text format     Abstract available


  173. ZHAO M, Liu MD, Pu YY, Wang D, et al
    Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2016;294:6-13.
    PubMed     Text format     Abstract available


  174. RIZZO R, Bortolotti D, Fainardi E, Gentili V, et al
    KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
    J Neuroimmunol. 2016;294:1-5.
    PubMed     Text format     Abstract available


  175. SINGH D, Torbey MT, Schwab JM
    Modifiable denominators of evolving post-stroke-autoimmunity.
    J Neuroimmunol. 2016 May 13. pii: S0165-5728(16)30106.
    PubMed     Text format    


    April 2016
  176. ZHANG M, Li XL, Li H, Wang S, et al
    Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity.
    J Neuroimmunol. 2016;293:129-36.
    PubMed     Text format     Abstract available


  177. ALVARENGA-FILHO H, Sacramento PM, Ferreira TB, Hygino J, et al
    Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators.
    J Neuroimmunol. 2016;293:91-9.
    PubMed     Text format     Abstract available


  178. RAE W, Burke G, Pinto A
    A study of the utility of azathioprine metabolite testing in myasthenia gravis.
    J Neuroimmunol. 2016;293:82-5.
    PubMed     Text format     Abstract available


  179. YAMOUT B, Karaky NM, Mahfouz RA, Jaber F, et al
    Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.
    J Neuroimmunol. 2016;293:59-64.
    PubMed     Text format     Abstract available


  180. BENEDEK G, Zhang J, Bodhankar S, Nguyen H, et al
    Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;293:45-53.
    PubMed     Text format     Abstract available


  181. YANG B, Lian Y, Liu Y, Wu BY, et al
    A retrospective analysis of possible triggers of Guillain-Barre syndrome.
    J Neuroimmunol. 2016;293:17-21.
    PubMed     Text format     Abstract available


  182. ZHANG DQ, Jia K, Wang R, Li T, et al
    Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;293:100-4.
    PubMed     Text format     Abstract available


  183. BRILL L, Mandel M, Karussis D, Petrou P, et al
    Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel.
    J Neuroimmunol. 2016;293:65-70.
    PubMed     Text format     Abstract available


  184. SHI Z, Chen H, Lian Z, Liu J, et al
    Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression.
    J Neuroimmunol. 2016;293:54-8.
    PubMed     Text format     Abstract available


  185. AKAISHI T, Nakashima I, Takeshita T, Mugikura S, et al
    Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.
    J Neuroimmunol. 2016;293:28-33.
    PubMed     Text format     Abstract available


    March 2016
  186. STERGIOU C, Lazaridis K, Zouvelou V, Tzartos J, et al
    Titin antibodies in "seronegative" myasthenia gravis - A new role for an old antigen.
    J Neuroimmunol. 2016;292:108-15.
    PubMed     Text format     Abstract available


  187. MELNIKOV M, Belousova O, Murugin V, Pashenkov capital EM, Cyrillic, et al
    The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.
    J Neuroimmunol. 2016;292:97-101.
    PubMed     Text format     Abstract available


  188. PATIL SA, Bokoliya SC, Nagappa M, Taly AB, et al
    Diagnosis of myasthenia gravis: Comparison of anti-nicotinic acetyl choline receptor antibodies, repetitive nerve stimulation and Neostigmine tests at a tertiary neuro care centre in India, a ten year study.
    J Neuroimmunol. 2016;292:81-4.
    PubMed     Text format     Abstract available


  189. SMOLDERS J, Muris AH, Damoiseaux J
    Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.
    J Neuroimmunol. 2016;292:79-80.
    PubMed     Text format    


  190. MAGNER WJ, Weinstock-Guttman B, Rho M, Hojnacki D, et al
    Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
    J Neuroimmunol. 2016;292:68-78.
    PubMed     Text format     Abstract available


  191. SUN Y, Tian T, Gao J, Liu X, et al
    Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice.
    J Neuroimmunol. 2016;292:58-67.
    PubMed     Text format     Abstract available


  192. BURMAN J, Raininko R, Blennow K, Zetterberg H, et al
    YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:52-7.
    PubMed     Text format     Abstract available


  193. BURMAN J, Svenningsson A
    Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:40-4.
    PubMed     Text format     Abstract available


  194. MARTIRE S, Navone ND, Montarolo F, Perga S, et al
    A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
    J Neuroimmunol. 2016;292:34-9.
    PubMed     Text format     Abstract available


  195. PUNGA T, Bartoccioni E, Lewandowska M, Damato V, et al
    Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
    J Neuroimmunol. 2016;292:21-6.
    PubMed     Text format     Abstract available


  196. MAKAR TK, Nimmagadda VK, Singh IS, Lam K, et al
    TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis.
    J Neuroimmunol. 2016;292:9-20.
    PubMed     Text format     Abstract available


  197. MAUSNER-FAINBERG K, Kolb H, Penn M, Regev K, et al
    Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-beta.
    J Neuroimmunol. 2016;292:93-6.
    PubMed     Text format     Abstract available


    February 2016
  198. FATEMI I, Shamsizadeh A, Ayoobi F, Taghipour Z, et al
    Role of orexin-A in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:101-9.
    PubMed     Text format     Abstract available


  199. HUIJBERS MG, Vink AF, Niks EH, Westhuis RH, et al
    Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.
    J Neuroimmunol. 2016;291:82-8.
    PubMed     Text format     Abstract available


  200. MIYAJI K, Paul F, Shahrizaila N, Umapathi T, et al
    Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases.
    J Neuroimmunol. 2016;291:78-81.
    PubMed     Text format     Abstract available


  201. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
    J Neuroimmunol. 2016;291:73-7.
    PubMed     Text format     Abstract available


  202. FORWELL AL, Bernales CQ, Ross JP, Yee IM, et al
    Analysis of CH25H in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2016;291:70-2.
    PubMed     Text format     Abstract available


  203. XIE C, Ciric B, Yu S, Zhang GX, et al
    IL-12Rbeta2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:59-69.
    PubMed     Text format     Abstract available


  204. MORIGUCHI K, Miyamoto K, Tanaka N, Ueno R, et al
    C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:54-8.
    PubMed     Text format     Abstract available


  205. IRELAND SJ, Guzman AA, Frohman EM, Monson NL, et al
    B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.
    J Neuroimmunol. 2016;291:46-53.
    PubMed     Text format     Abstract available


  206. SHINODA K, Sun X, Oyamada A, Yamada H, et al
    Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:39-45.
    PubMed     Text format     Abstract available


  207. MADEIRA A, Burgelin I, Perron H, Curtin F, et al
    MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
    J Neuroimmunol. 2016;291:29-38.
    PubMed     Text format     Abstract available


  208. ZAHEDNASAB H, Karampoor S
    The correlation of HLA-G with multiple sclerosis.
    J Neuroimmunol. 2016;291:28.
    PubMed     Text format    


  209. BLAIR TC, Manoharan M, Rawlings-Rhea SD, Tagge I, et al
    Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.
    J Neuroimmunol. 2016;291:1-10.
    PubMed     Text format     Abstract available


  210. ZHANG W, Jiao Y, Cui L, Jiao J, et al
    Differentiation of neuromyelitis optica spectrum disorders from ultra-longitudinally extensive transverse myelitis in a cohort of Chinese patients.
    J Neuroimmunol. 2016;291:96-100.
    PubMed     Text format     Abstract available


    January 2016
  211. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility.
    J Neuroimmunol. 2016;290:115-8.
    PubMed     Text format     Abstract available


  212. KHORRAMDELAZAD H, Bagheri V, Hassanshahi G, Zeinali M, et al
    New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis.
    J Neuroimmunol. 2016;290:70-5.
    PubMed     Text format     Abstract available


  213. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Expression of DNA methylation genes in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;290:66-9.
    PubMed     Text format     Abstract available


  214. ARUMUGAM M, Parthasarathy V
    Reduction of CD4(+)CD25(+) regulatory T-cells in migraine: Is migraine an autoimmune disorder?
    J Neuroimmunol. 2016;290:54-9.
    PubMed     Text format     Abstract available


  215. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study.
    J Neuroimmunol. 2016;290:47-8.
    PubMed     Text format     Abstract available


  216. MORENO MA, Burns T, Yao P, Miers L, et al
    Therapeutic depletion of monocyte-derived cells protects from long-term axonal loss in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;290:36-46.
    PubMed     Text format     Abstract available


  217. FISCHER HJ, van den Brandt J, Lingner T, Odoardi F, et al
    Modulation of CNS autoimmune responses by CD8(+) T cells coincides with their oligoclonal expansion.
    J Neuroimmunol. 2016;290:26-32.
    PubMed     Text format     Abstract available


  218. SUNWOO JS, Chu K, Byun JI, Moon J, et al
    Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders.
    J Neuroimmunol. 2016;290:15-21.
    PubMed     Text format     Abstract available


  219. HASSON T, Kolitz S, Towfic F, Laifenfeld D, et al
    Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    J Neuroimmunol. 2016;290:84-95.
    PubMed     Text format     Abstract available


  220. MAURER MA, Tuller F, Gredler V, Berger T, et al
    Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
    J Neuroimmunol. 2016;290:49-53.
    PubMed     Text format     Abstract available


    December 2015
  221. SUAREZ-CALVET X, Gallardo E, Illa I
    Comment to "Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis".
    J Neuroimmunol. 2015 Dec 18. pii: S0165-5728(15)30101.
    PubMed     Text format    


  222. FUHLHUBER V, Bick S, Tschernatsch M, Dharmalingam B, et al
    Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
    J Neuroimmunol. 2015;289:182-6.
    PubMed     Text format     Abstract available


  223. LEE CY, Lam CL, Pang SY, Lau KK, et al
    Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese.
    J Neuroimmunol. 2015;289:177-81.
    PubMed     Text format     Abstract available


  224. LOSHAJ-SHALA A, Regazzoni L, Daci A, Orioli M, et al
    Guillain Barre syndrome (GBS): new insights in the molecular mimicry between C. jejuni and human peripheral nerve (HPN) proteins.
    J Neuroimmunol. 2015;289:168-76.
    PubMed     Text format     Abstract available


  225. SHENG JR, Quan S, Soliven B
    IL-10 derived from CD1d(hi)CD5(+) B cells regulates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2015;289:130-8.
    PubMed     Text format     Abstract available


  226. MOHAJERI M, Sadeghizadeh M, Javan M
    Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
    J Neuroimmunol. 2015;289:105-10.
    PubMed     Text format     Abstract available


  227. CHAUDHARY P, Marracci G, Galipeau D, Pocius E, et al
    Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2015;289:68-74.
    PubMed     Text format     Abstract available


  228. ALEXOPOULOS H, Kampylafka EI, Fouka P, Tatouli I, et al
    Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.
    J Neuroimmunol. 2015;289:8-11.
    PubMed     Text format     Abstract available


  229. HORELLOU P, Wang M, Keo V, Chretien P, et al
    Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    J Neuroimmunol. 2015;289:1-7.
    PubMed     Text format     Abstract available


  230. SIUKO M, Valori M, Kivela T, Setala K, et al
    Exome and regulatory element sequencing of neuromyelitis optica patients.
    J Neuroimmunol. 2015;289:139-42.
    PubMed     Text format     Abstract available


  231. YAMOUT BI, Zeineddine MM, Tamim H, Khoury SJ, et al
    Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
    J Neuroimmunol. 2015;289:93-7.
    PubMed     Text format     Abstract available


  232. KANG H, Cao S, Chen T, Jiang Z, et al
    The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain.
    J Neuroimmunol. 2015;289:56-61.
    PubMed     Text format     Abstract available


    November 2015
  233. TANAKA M, Kinoshita M
    Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
    J Neuroimmunol. 2015;288:69.
    PubMed     Text format     Abstract available


  234. ARVIDSSON L, Covacu R, Estrada CP, Sankavaram SR, et al
    Long-distance effects of inflammation on differentiation of adult spinal cord neural stem/progenitor cells.
    J Neuroimmunol. 2015;288:47-55.
    PubMed     Text format     Abstract available


  235. RAMIREZ GA, Lanzani C, Bozzolo EP, Citterio L, et al
    TRPC6 gene variants and neuropsychiatric lupus.
    J Neuroimmunol. 2015;288:21-4.
    PubMed     Text format     Abstract available


    October 2015
  236. MEALY MA, Levy M
    Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
    J Neuroimmunol. 2015;287:29-30.
    PubMed     Text format     Abstract available


  237. KON T, Nishijima H, Haga R, Funamizu Y, et al
    Hypertrophic pachymeningitis accompanying neuromyelitis optica spectrum disorder: A case report.
    J Neuroimmunol. 2015;287:27-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: